"CA-19-9 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
| Descriptor ID |
D018395
|
| MeSH Number(s) |
D23.050.285.050.119 D23.050.301.290.544.119 D23.050.550.325.119 D23.050.705.230.544.119 D23.101.140.075.119
|
| Concept/Terms |
CA-19-9 Antigen- CA-19-9 Antigen
- Antigen, CA-19-9
- CA 19 9 Antigen
- CA 19.9 Antigen
- Antigen, CA 19.9
- Gastrointestinal Cancer Antigen
- Cancer Antigen, Gastrointestinal
- CA 19-9 Antigen
- Antigen, CA 19-9
- Antigen CA-19-9
- Antigen CA 19 9
- CA-19-9, Antigen
|
Below are MeSH descriptors whose meaning is more general than "CA-19-9 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CA-19-9 Antigen".
This graph shows the total number of publications written about "CA-19-9 Antigen" by people in this website by year, and whether "CA-19-9 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 3 | 4 |
| 2006 | 1 | 2 | 3 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CA-19-9 Antigen" by people in Profiles.
-
Weitzenfeld P, Bournazos S, Ravetch JV. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. J Clin Invest. 2019 09 03; 129(9):3952-3962.
-
Lowder CY, Metkus J, Epstein J, Kozak GM, Lavu H, Yeo CJ, Winter JM. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4004-4011.
-
Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 08; 39(4):340-5.
-
De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014 Apr 15; 89(8):626-32.
-
Kang CY, Wang J, Axell-House D, Soni P, Chu ML, Chipitsyna G, Sarosiek K, Sendecki J, Hyslop T, Al-Zoubi M, Yeo CJ, Arafat HA. Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2014 Jan; 18(1):7-15.
-
Auriemma WS, Berger AC, Bar-Ad V, Boland PM, Cohen SJ, Roche-Lima CM, Morris GJ. Locally advanced pancreatic cancer. Semin Oncol. 2012 Aug; 39(4):e9-22.
-
Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013 Jan; 107(1):15-22.
-
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, Macdonald J, Willett CG. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 =90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):e291-7.
-
Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg. 2011; 45:301-21.
-
Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011 Jun 15; 117(12):2620-8.